Phase 3 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are in generally stable health, based on a physical exam, blood tests, heart tracing (ECG), and medical history done at the screening visit.
- You have been diagnosed with myasthenia gravis (MG) that affects muscles throughout your body (not just your eyes), and your condition falls into a moderate-to-severe category as defined by a standard MG grading system (MGFA class II, III, or IV).
- Your blood test shows a specific antibody linked to MG (called acetylcholine receptor, or AChR, antibody).
- Your MG symptoms score on a daily living questionnaire (MG-ADL) is 5 or higher, and fewer than half of those points come from eye-related symptoms — measured at both your screening and first study visits.
If you are joining Arms 1 or 2 only:
- Your current MG treatment is not working well enough, according to your doctor, OR you have stopped certain MG medications (such as steroids or immune-suppressing drugs) at least 4 weeks before the study starts, because they caused side effects or did not work.
If you are joining Arm 3 only:
- You have already received at least one full course of a specific MG treatment called efgartigimod (given by drip or injection), and your last course followed the standard guidelines for that medicine.
Who may not be able to join:
- You have a confirmed or suspected immune system disorder unrelated to your MG treatment, or you have a family history of an inherited immune system condition (unless tests confirm you do not have it).
- You had your thymus gland removed (thymectomy) within the past year, or you are planning to have this surgery during the study.
- You currently have cancer, or you have had cancer at any point in the 3 years before joining the study.
If you are joining Arms 1 or 2 only:
- You have previously been treated for MG with a type of medication that targets a protein called FcRn (confirm with trial site if unsure whether your medication falls into this category).
If you are joining Arm 3 only:
- You are currently taking certain types of medications called IgG monoclonal antibodies or similar treatments (including some replacement therapies), unless that medication is efgartigimod.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Arms 1 and 2: Averaged Mean Percent Change from Baseline in Total Immunoglobulin G (IgG) Levels Over Weeks 8, 10 and 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.